Home › Chronic Myeloid Leukemia › New York › Rochester
Chronic Myeloid Leukemia clinical trials in Rochester, NY
4 studies for Chronic Myeloid Leukemia are looking for participants at sites in and around Rochester (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Study of Olverembatinib (HQP1351) in Patients With CML-CP
RecruitingPhase 3
- Ascentage Investigative Site #1068, Rochester
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
RecruitingObservational study
- Strong Memorial Hospital/University of Rochester, Rochester
Impact of Targeted Therapy on Cancer-Related Cognitive Impairment
RecruitingObservational studyHealthy volunteers welcome
- University of Rochester NCORP Research Base, Rochester
Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant
RecruitingEarly phase 1
- Wilmot Cancer Institute, University of Rochester, Rochester
About Chronic Myeloid Leukemia
Chronic myeloid leukemia (CML) is a cancer of the white blood cells. It usually affects older adults. Learn about symptoms, genetics, and treatment.
More about Chronic Myeloid Leukemia on MedlinePlus
Chronic Myeloid Leukemia trials in other cities
- Houston, TX18 studies
- Seattle, WA11 studies
- New York City, NY11 studies
- Detroit, MI6 studies
- Birmingham, AL6 studies
- Chicago, IL6 studies
- Portland, OR6 studies
- Philadelphia, PA6 studies
- Baldwin Park, CA6 studies
- Nashville, TN5 studies
- Columbus, OH5 studies
- Baltimore, MD5 studies
Other studies in Rochester
- Acute Myeloid Leukemia16 studies
- Lung Cancer15 studies
- Breast Cancer15 studies
- Cancer (all types)14 studies
- Obesity14 studies
- Non-Small Cell Lung Cancer13 studies
- Overweight13 studies
- Prostate Cancer10 studies
- Multiple Myeloma8 studies
- Metastatic Cancer8 studies
- Pancreatic Cancer7 studies
- Myotonic Dystrophy7 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.